T cell Isolation from Whole Blood
using 50nm Superparamagnetic IngenuityTM Beads
Simplified, time-saving T cell isolation process directly from Whole Blood
The therapeutic efficacy of chimeric antigen receptor (CAR) T cells in hematologic malignancies underscores the urgency for a cost-effective manufacturing process. T cell isolation, a crucial upstream step, significantly influences T cell quality and therapy success.
Isolating T cells for CAR T cell therapy directly from whole blood, utilizing the MARS® Bar platform and IngenuityTM 50nm beads, offers several advantages:
– it simplifies the process by reducing the number of required manipulations, enhancing efficiency and cost-effectiveness
– saves time by eliminating the need for additional centrifugation and purification steps, crucial in urgent scenarios where fast production of CAR T cells is key.
Through the unique capability to directly isolate T cells from whole blood, researchers can reliably achieve the separation of T cells with high purity and yield using the MARS® Bar platform. T cells were isolated directly from whole blood using IngenuityTM CD4 and CD8 nanobeads.
Starting with an initial average T cell purity of 28%, T cell positive selection using the IngenuityTM 50nm CD4 and CD8 beads on the MARS® Bar system resulted in an average recovery rate of 75% T cells with a mean purity of 94%. An evaluation of viability before and after the separation demonstrated improved viability in the output sample.
Our quality commitment
AUTOMATION MEETS INNOVATION
MARS® Bar – one platform for both T cell enrichment and CAR-T cell harvest
- Column-free, closed, sterile fluidics system
- ISO 13485:2016 certified and GMP-ready
- Compatible with fresh or frozen leukopak
- Solution optimized for Applied Cells’ IngenuityTM reagents
